U.S. markets closed

Vermilion Energy Inc. (VET)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
6.26-0.03 (-0.48%)
At close: 4:00PM EST

6.30 +0.04 (0.64%)
After hours: 5:28PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close6.29
Bid6.16 x 3200
Ask6.41 x 800
Day's Range6.19 - 6.53
52 Week Range1.50 - 10.98
Avg. Volume2,443,950
Market Cap995.59M
Beta (5Y Monthly)3.62
PE Ratio (TTM)N/A
EPS (TTM)-0.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 30, 2020
1y Target Est42.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-19% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Self-Portrait Unveils Its Autumn Winter 2021 Collection with a Series of Images Starring Phoebe Dynevor
    CNW Group

    Self-Portrait Unveils Its Autumn Winter 2021 Collection with a Series of Images Starring Phoebe Dynevor

    24, 2021 /CNW/ -- Self-Portrait has today unveiled its Autumn Winter 2021 Collection through a series of images and film featuring British actress Phoebe Dynevor. Captured in Self-Portrait's hometown of London, the images were shot by British photographer Nigel Shafran encapsulating the mood of the moment and presenting a snapshot of a day at home with Phoebe, finding joy in simplicity and solitude.

  • Moving Average Crossover Alert: Vermilion Energy (VET)

    Moving Average Crossover Alert: Vermilion Energy (VET)

    Vermilion Energy (VET) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

  • Vermilion Energy Lowers 2021 Exploration Budget To $300M

    Vermilion Energy Lowers 2021 Exploration Budget To $300M

    Canadian oil and gas producer Vermilion Energy has approved an exploration and development (E&D) capital budget of $300 million for 2021. The capital budget is 17% lower than in the year-ago period. Vermilion Energy (VET) said that it aims to utilize the 2021 capital budget in maximizing returns, improving free cash flow, and facilitate debt reduction. The company said, “Our $300 million capital program is fully funded at a WTI [West Texas Intermediate] oil price of approximately $37/bbl [barrel of oil] on an unhedged basis, assuming all other commodity prices held at the January 13, 2021 commodity strip.” The energy producer also expects its capital program to deliver annual average production of 83,000 to 85,000 boe/d [barrels of oil equivalent per day]. (See VET stock analysis on TipRanks) On Jan. 15, Raymond James analyst Chris Cox upgraded the stock to Buy from Hold and also raised the price target to $6.27 (17.4% upside potential). The analyst cites significant improvement in the company’s outlook after revising commodity price assumptions. Unlike Cox, the rest of the Street is sidelined on the stock with the analyst consensus of a Hold based on 6 Holds, 2 Buys and 1 Sell. The average analyst price target of $5.26 implies downside potential of about 1.5% to current levels. Shares have declined 65.8% in one year. Related News:China’s Tencent Music To Snap Up Lazy Audio For $417M; Street Is BullishVail Resorts Sees Lower Ski Traffic in North AmericaXPeng To Roll Out Autonomous Driving Feature For Highways More recent articles from Smarter Analyst: Turquoise Hill Expects Higher Gold Production In 2021 MasterCraft Is Going Digital For Its Dynamic Boat Show Season Quest Diagnostics Wins Covid-19 Contract With US Health Agency Palantir’s Covid-19 Contract With US Government Under Threat - Report